Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Forimtamig Combinations in Relapsed or Refractory Multiple Myeloma
NCT06055075Phase 2Terminated
- Sponsor
- Roche
- Start
- Dec 2023
- Primary completion
- Jul 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of forimtamig in multiple myeloma (MM), sponsored by Roche. Started Dec 2023; status: terminated.
02
Drugs
forimtamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06055075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06055075.